Harmony Biosciences obtains $200 million debt facility via CR Group

By Sarah Lizee

Olympia, Wash., March 13 – Harmony Biosciences, LLC entered into a $200 million debt facility with CR Group LP, according to a press release.

Proceeds will be used to provide additional working capital.

On Feb. 12, the FDA accepted for filing the New Drug Application for Harmony’s investigational product, pitolisant, a histamine 3 receptor antagonist/inverse agonist for the potential treatment of excessive daytime sleepiness and/or cataplexy in adult patients with narcolepsy.

“CRG is pleased to provide Harmony with flexible financing options as the company prepares to launch its anticipated treatment for narcolepsy in the U.S. and change the treatment landscape within this rare disease category,” Luke Duster, partner of CR Group, said in the release.

Plymouth Meeting, Pa.-based Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing novel treatment options for people living with rare diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.